The stock tadawul 4007, representing Al-Hamadi Holding, is one of the prominent stocks listed in the healthcare sector of the Saudi financial market (Tadawul). This stock holds significant importance among investors and those interested in the healthcare sector due to the company's history, ongoing expansion, and its role in achieving the goals of Saudi Vision 2030. In recent years, Al-Hamadi Holding has witnessed remarkable growth in its revenues and profits, in addition to expanding into new projects in Mecca and digital health initiatives. The stock trades under the symbol 4007 and is characterized by relative stability in financial performance and moderate trading volume, making it a point of interest for many analysts and market followers. In this article, we will provide a comprehensive analytical overview of the stock tadawul 4007, reviewing financial performance, the company's strategic directions, its position in the healthcare sector, as well as the latest news and developments, while adhering to the Capital Market Authority's regulations by not providing investment advice or price forecasts, and focusing on presenting financial and analytical information in an educational and neutral manner.
Overview of Al-Hamadi Holding and Stock tadawul 4007
Al-Hamadi Holding is one of the largest Saudi companies specializing in the healthcare sector, established to provide high-quality medical services through a network of hospitals and clinics across the Kingdom. The company is listed on the Saudi financial market (Tadawul) under the symbol 4007 within the healthcare sector – healthcare service providers. The stock is part of medium market capitalization companies, granting it significant standing in the market, especially amid government trends to increase the private sector's contribution to healthcare services. The company continues to enhance its capabilities through investments in expansion projects, such as building new hospitals and adopting digital medical transformation, in line with the Kingdom's upcoming requirements and Vision 2030.
Recent Financial Performance of Al-Hamadi Holding (tadawul 4007)
During 2024 and early 2025, Al-Hamadi Holding's financial data showed stable performance with notable growth in revenues and profits. The stock price in mid-February 2025 was approximately SAR 27.92 per share, while the market capitalization ranged between SAR 4.2 billion and SAR 4.6 billion. The company recorded revenue growth of about 10-15% for the first half of 2024 compared to the same period in 2023, and net profit increased by nearly 5%. The price-to-earnings (P/E) ratio for the company is around 16-17 times for 2025, with expectations of a decrease to 14-15 times in 2026 due to anticipated profit increases. Annual dividends have ranged in recent years from approximately 2-3% of the stock value. These indicators reflect relative financial stability and a gradual growth trend for the company.
Saudi Healthcare Sector: Opportunities and Challenges for Al-Hamadi 4007
The healthcare sector in Saudi Arabia is experiencing significant development driven by increased government spending, population growth, and the Vision 2030 initiatives to enhance the role of the private sector. Al-Hamadi Holding benefits from this positive environment through the expansion of its projects and entry into digital health fields. On the other hand, the company faces challenges including intense competition from major companies like Dallah Healthcare and Al-Mowasat, pricing pressures from the Ministry of Health, and a shortage of specialized medical personnel. Nevertheless, Al-Hamadi is distinguished by its strong relationships with government entities and its experience in managing and operating hospitals, along with its ability to adapt to digital transformations in the sector.
Analysis of Al-Hamadi's Main Competitors (tadawul 4007)
Al-Hamadi Holding competes with several major companies in the Saudi healthcare sector, including Dallah Healthcare (Tadawul: 1010), Al-Mowasat (Tadawul: 4006), and Waha (Tadawul: 3451). Dallah Healthcare has a larger asset base and is spread across many regions, while Al-Mowasat focuses on modern medical specialties. Al-Hamadi stands out with its ability to diversify its services and target densely populated areas such as Mecca. Financially, Al-Hamadi achieves moderate profitability compared to its larger competitors, but its strategy of digital expansion and new projects may provide it with a future competitive advantage.
Recent Developments and News Impacting Al-Hamadi Holding Stock
Recently, several important developments concerning Al-Hamadi Holding stock have occurred. Notably, the company acquired 40% of the shares of Farid Medical, enhancing its focus on digital health. The company is also continuing to develop the large Mecca hospital project, with expectations to open new phases in 2025. Al-Hamadi has participated in government partnerships to improve healthcare services and is seeking to win new operational contracts with the Ministry of Health. The financial results for the first half of 2024 showed an increase in revenues and net profit, reflecting stability in the stock's performance in the market. No significant negative news has emerged recently, supporting investor confidence in the company's continuity.
Dividends and Return Policy for Al-Hamadi Stock (4007)
Al-Hamadi Holding adopts an annual dividend distribution policy for shareholders after the approval of the general assembly, with distribution ratios in recent years ranging between 2% and 3% of the stock value. In 2023, for example, the company distributed cash dividends equivalent to 5-7% of the capital. Distribution decisions are influenced by annual financial performance and market conditions. It is noted that Al-Hamadi maintains a stable distribution trend, although the dividend yield is not considered high compared to some other companies in the sector, as the company prefers to retain a portion of profits to support expansion and digital transformation projects.
Digital Expansion Strategy and Transformation in Al-Hamadi Services
Al-Hamadi Holding recognizes the importance of digital transformation in the healthcare sector, which is why it has invested in technology companies like Farid Medical, in addition to developing its own digital platforms and medical applications. Digital transformation enhances the efficiency of medical operations, improves patient experience, and aligns with government trends towards e-health. The company also aims to expand home and virtual healthcare services, positioning it competitively to meet future market demands and growth expectations in the Saudi healthcare sector.
Stock Performance and Trading Volume in 2024
Al-Hamadi Holding's stock traded between SAR 25 and SAR 33 per share during 2024, with relatively limited fluctuations. The average daily trading volume in some sessions was 170-180 thousand shares, reflecting moderate interest from investors compared to leading stocks in the sector. The stock gradually rose with the announcement of positive financial results, then stabilized by the end of the year due to continuous profits and revenue growth. Fluctuations in the stock price reflected the dynamics of the health market and local economic conditions, yet the stock's performance remained balanced due to the company's stable financial fundamentals.
Impact of Saudi Vision 2030 on Al-Hamadi Holding Strategy
Saudi Vision 2030 plays a pivotal role in reshaping the healthcare sector, focusing on increasing the private sector's contribution, enhancing quality, and supporting digital transformation. Al-Hamadi Holding benefits from these trends by participating in public-private partnership projects and expanding its service portfolio. Government initiatives also provide opportunities for the company to win new operational and management contracts and participate in modern hospital construction projects. This direction supports the company's sustainable growth and enhances the attractiveness of its stock in the Saudi market.
Strengths and Weaknesses in Al-Hamadi Holding Stock Performance
Key strengths of Al-Hamadi stock include financial stability, continuous revenue growth, good relationships with government entities, and the ability to expand into new projects. The company's investments in digital transformation enhance its position in the future market. Conversely, the company faces challenges related to intense competition, fluctuations in healthcare demand, and pricing pressures from regulatory bodies. The company's profitability remains average compared to major competitors, which may require enhancing operational efficiency and developing new services to increase profit margins in the future.
Overview of Key Financial Indicators for Al-Hamadi (tadawul 4007)
Recent financial indicators for Al-Hamadi Holding show stability in performance. The stock price stabilized in the range of SAR 27-28 in the first quarter of 2025, with a market value estimated at approximately SAR 4.25 billion. The price-to-earnings (P/E) ratio was about 16.7 times for 2025, and improvement is expected in 2026 with increased profits. The dividend yield has been around 2-3% in recent years. The company also experienced annual revenue growth of about 10-15%, reflecting its ability to increase its market share in a competitive environment.
Developments in Al-Hamadi's Major Projects and Future Initiatives
Al-Hamadi Holding aims to strengthen its position through major expansion projects, such as the Mecca hospital, which is expected to be one of the largest hospitals in the region upon its opening. The company is also investing in digital initiatives and partnerships with technology companies to enhance its services in virtual health. The company continues to explore expansion opportunities in Riyadh and Jeddah through partnership contracts with the Ministry of Health. These future projects reflect the company's vision for sustainable growth and meeting the changing needs of the healthcare sector.
Risks and Future Challenges for Al-Hamadi Holding Stock
Al-Hamadi Holding stock faces several potential risks, such as changes in demand for healthcare services, intense competition from major companies, and government policies related to pricing or health insurance contracts. Additionally, rising operational costs and a shortage of specialized medical personnel represent ongoing challenges. However, the company possesses extensive crisis management experience and the ability to adapt to changes, enhancing its resilience in dealing with future challenges.
Conclusion
In conclusion, the stock tadawul 4007 (Al-Hamadi Holding) exemplifies Saudi healthcare companies that have successfully achieved stable growth and strategic expansions in line with the aspirations of Saudi Vision 2030. The company features balanced financial indicators, a clear digital transformation strategy, and a continuous focus on developing its services and medical infrastructure. However, the healthcare sector remains subject to competitive, regulatory, and economic challenges that require investors and observers to conduct thorough studies of all variables before making any financial decisions. We always recommend consulting a licensed financial advisor before investing in any stock or making financial decisions. For more insights on Al-Hamadi Holding's performance and analysis of the Saudi market, you can follow the SIGMIX platform, which provides high-quality educational and analytical content on Saudi stocks and listed companies.
Frequently Asked Questions
Stock tadawul 4007 represents Al-Hamadi Holding, a Saudi company specialized in healthcare listed on the Saudi Tadawul market. The stock is distinguished by being part of a sector experiencing rapid growth in the Kingdom, with relative financial stability and clear trends towards expansion and digital transformation. The company's performance in recent years reflects its ability to achieve gradual growth in revenues and profits, making the stock an option of interest to investors in the Saudi market.
Al-Hamadi Holding's stock price fluctuated during 2024 between SAR 25 and SAR 33, stabilizing in the second half of the year near SAR 27.92 per share in mid-February 2025. The stock gradually rose with the announcement of positive financial results and improved economic conditions, then stabilized by the end of the year due to the balance of supply and demand and investor confidence in the company's performance. The fluctuations were relatively limited compared to some other healthcare sector stocks.
Current financial indicators for Al-Hamadi stock include a share price of approximately SAR 27.92, a market value of about SAR 4.25 billion, a price-to-earnings (P/E) ratio of 16-17 times for 2025, and a dividend yield between 2-3%. The company also experienced revenue growth of 10-15% for the first half of 2024, with a 5% increase in net profit. These indicators reflect stable financial performance with a trend towards continuous growth.
Al-Hamadi Holding follows an annual cash dividend distribution policy after the approval of the general assembly, with distribution ratios in recent years ranging between 2% and 3% of the stock value. In 2023, distributions amounted to about 5-7% of the capital. The distribution policy is based on the company's annual financial performance, considering expansion plans and retaining a portion of profits to support future projects.
Al-Hamadi Holding benefits from Vision 2030 by expanding the role of the private sector in healthcare, participating in public-private partnership projects, and benefiting from increased government spending on digital health and modern hospitals. The vision also enhances the company's opportunities to win new operational and management contracts and expand its presence in the Saudi market, supporting its sustainable growth and service development.
Among Al-Hamadi's current major projects is the large Mecca hospital expected to open gradually in 2025, and the company's acquisition of 40% of Farid Medical to enhance digital transformation. The company is also exploring expansion opportunities in major cities like Riyadh and Jeddah through partnership contracts with the Ministry of Health. Additionally, the company focuses on developing digital health services and home healthcare to align with modern trends in the sector.
Al-Hamadi Holding's main competitors in the Saudi market include Dallah Healthcare (Tadawul: 1010), Al-Mowasat (Tadawul: 4006), and Waha (Tadawul: 3451). The company also competes with government and semi-government healthcare institutions, as well as private companies focusing on specialized areas or digital services. Al-Hamadi is distinguished by its focus on expanding in large urban areas and investing in digital projects.
Risks and challenges include intense competition from major companies, changes in demand for healthcare services, government policies related to pricing or insurance, rising operational costs, and a shortage of specialized medical personnel. The healthcare sector is also sensitive to economic fluctuations and pandemics, requiring the company to maintain high flexibility in crisis management and adaptation to developments.
Performance of Al-Hamadi stock can be followed through official platforms like the Saudi Tadawul website, in addition to financial analysis sites like Mubasher and MarketScreener. These sources provide periodic reports on stock price, financial data, and company news. Educational platforms like SIGMIX also offer in-depth analyses of Saudi stocks and listed companies, including Al-Hamadi Holding.
Investing in stocks in general, including Al-Hamadi stock, depends on the investor's financial goals, risk tolerance, and market knowledge. Given market fluctuations and factors affecting the healthcare sector, it is always advisable to consult a licensed financial advisor before making any investment or financial decisions, and not to rely solely on general analyses or market news.